Welcome to our dedicated page for Lumos Pharma news (Ticker: LUMO), a resource for investors and traders seeking the latest updates and insights on Lumos Pharma stock.
Lumos Pharma Inc (NASDAQ: LUMO) is a clinical-stage biotechnology company pioneering therapies for rare endocrine disorders, with a focus on pediatric growth hormone deficiencies. This page aggregates official press releases, clinical trial updates, and strategic developments directly from the company and verified sources.
Investors and stakeholders will find timely updates on LUMO’s pipeline progress, including its lead oral growth hormone secretagogue LUM-201, regulatory milestones, and collaborative research initiatives. The curated content spans clinical data disclosures, partnership announcements, and scientific presentations relevant to rare disease therapeutics.
Key categories include Phase 2 trial results, FDA communications, intellectual property updates, and research collaborations. All materials are sourced to ensure compliance with financial reporting standards and medical accuracy.
Bookmark this page for streamlined access to Lumos Pharma’s latest advancements in transforming treatment paradigms for underserved patient populations. Regularly updated to reflect the company’s evolving role in rare disease innovation.
Lumos Pharma announced that new analyses from its Phase 2 OraGrowtH210 and OraGrowtH212 clinical trials will be presented at the 2024 Annual Meeting of the Endocrine Society (ENDO) in Boston from June 1-4, 2024.
The two posters cover significant findings in pediatric growth hormone deficiency treatments. The first, presented by Dr. Fernando Cassorla, focuses on oral LUM-201 and its ability to restore growth hormone secretion in children. The second, by Dr. Adam Stevens, examines how growth responses to LUM-201 depend on the pattern of hormone secretion.
Lumos Pharma reported positive outcomes from its End-of-Phase 2 meeting with the FDA, supporting a placebo-controlled Phase 3 trial of LUM-201. The company shared promising 12 and 24-month data from Phase 2 OraGrowtH trials, showing significant growth increases from baseline. Full 12-month data demonstrated AHVs of 8.2 cm/yr and 7.6 cm/yr at 6 and 12 months, respectively. Financially, Lumos Pharma reported a net loss of $10.4 million for Q1 2024, with cash reserves of $23.2 million, expected to support operations through Q3 2024. R&D expenses rose to $7.2 million, while G&A expenses decreased to $3.8 million.
Lumos Pharma, Inc. (NASDAQ:LUMO) will report its first quarter 2024 financial results on May 15, 2024, focusing on therapeutics for rare diseases. The company will host a conference call to discuss financial results and provide updates on clinical and corporate activities. Investors and the public can participate in the call and access the webcast.
FAQ
What is the current stock price of Lumos Pharma (LUMO)?
What is the market cap of Lumos Pharma (LUMO)?
